Current antimicrobial treatment recommendations for melioidosis, the disease caused by Burkholderia pseudomallei, are largely based on studies of strains isolated from the Eastern Hemisphere (EH), where most human cases are identified and reported. In this study, we evaluated the antimicrobial susceptibility of 26 strains in the CDC (Centers for Diseases Control and Prevention) collection from the Western Hemisphere (WH) isolated from 1960 to 2015. Minimal inhibitory concentration (MIC) values were measured by standard broth microdilution for 16 antimicrobials following Clinical and Laboratory Standards Institute (CLSI) guidelines. Twenty-four of the 26 WH strains were susceptible to the six antimicrobials with CLSI-defined MIC susceptibility interpretive criteria for B. pseudomallei: amoxicillin/clavulanate, ceftazidime, imipenem, doxycycline, tetracycline, and trimethoprim/sulfamethoxazole. One WH strain demonstrated intermediate amoxicillin/clavulanate resistance and another strain had intermediate resistance to tetracycline. For all antimicrobials tested, the susceptibility profiles of WH isolates were comparable with previously reported MIC results of EH strains. The overall similarities suggest that the same antimicrobials are useful for melioidosis treatment in both the WH and EH. Using in silico analyses of WH genomes, we identified a novel amino acid substitution P258S in the beta-lactamase PenA, which may contribute to decreased susceptibility to amoxicillin/clavulanate in B. pseudomallei.
LimmathurotsakulD., GoldingN., DanceD.A, MessinaJ.P, PigottD.M, MoyesC.L, RolimD.B, BertheratE., DayN.P, PeacockS.J, and HayS.I.. 2016. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. 1:15008.
3.
RolimD.B., LimaR.X.R, RibeiroA.K.C, ColaresR.M, LimaL.D.Q, Rodriguez-MoralesA.J, MontufarF.E, and DanceD.A.B. 2018. Melioidosis in South America. Trop. Med. Infect. Dis. 3:60.
4.
GeeJ.E., GulvikC.A, ElrodM.G, BatraD., RoweL.A, ShethM., and HoffmasterA.R.. 2017. Phylogeography of Burkholderia pseudomallei isolates, Western Hemisphere. Emerg. Infect. Dis. 23:1133–1138.
5.
ChewapreechaC., HoldenM.T, VehkalaM., ValimakiN., YangZ., HarrisS.R, MatherA.E, TuanyokA., De SmetB., Le HelloS., BizetC., MayoM., WuthiekanunV., LimmathurotsakulD., PhetsouvanhR., SprattB.G, CoranderJ., KeimP., DouganG., DanceD.A, CurrieB.J, ParkhillJ., and PeacockS.J.. 2017. Global and regional dissemination and evolution of Burkholderia pseudomallei. Nat. Microbiol. 2:16263.
6.
TorresA.G., MontufarF.E, GeeJ.E, HoffmasterA.R, ElrodM.G, Duarte-ValderramaC., HuertasM.G, and BlaneyD.D.. 2018. Melioidosis is in the Americas: a call to action for diagnosing and treating the disease. Am. J. Trop. Med. Hyg. 99:563–564.
7.
Meza-RadillaG., Mendez-CanariosA., Xicohtencatl-CortesJ., Escobedo-GuerraM.R, TorresA.G, IbarraJ.A, and Estrada-de Los SantosP.. 2019. Misidentification of Burkholderia pseudomallei and other Burkholderia species from pediatric infections in Mexico. Open Forum Infect. Dis. 6:ofz008.
8.
ChaowagulW., ChierakulW., SimpsonA.J, ShortJ.M, StepniewskaK., MaharjanB., RajchanuvongA., BusarawongD., LimmathurotsakulD., ChengA.C, WuthiekanunV., NewtonP.N, WhiteN.J, DayN.P, and PeacockS.J.. 2005. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob. Agents Chemother. 49:4020–4025.
9.
AhmadN., HashimR., and Mohd NoorA.. 2013. The in vitro antibiotic susceptibility of Malaysian isolates of Burkholderia pseudomallei. Int. J. Microbiol. 2013:121845.
10.
Ashdown, L.R. 1979. An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology, 11:293–297.
11.
Volpe-ChavesC.E., RodriguesA.C.S, LacerdaM., OliveiraC.T.F, CastilhoS.B, FranciscatoC., SantosI.C.O, AssefA., RoeverL., OliveiraS., and PaniagoA.M.M. 2019. Melioidosis, an emerging infectious disease in the Midwest Brazil: a case report. Medicine (Baltimore), 98:e15235.
12.
RodriguezJ.Y., Morales-LopezS.E, RodriguezG.J, Alvarez-MorenoC.A, EsqueaK., PinzonH., RamirezL.R, MorenoL., OcampoW., and CepedaM.L.. 2019. Case series study of melioidosis, Colombia. Emerg. Infect. Dis. 25:1531–1534.
13.
JenneyA.W., LumG., FisherD.A, and CurrieB.J.. 2001. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents, 17:109–113.
14.
MaloneyS., EnglerC., and NortonR.. 2017. Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method. J. Glob. Antimicrob. Resist. 10:291–294.
15.
SaipromN., AmornchaiP., WuthiekanunV., DayN.P, LimmathurotsakulD., PeacockS.J, and ChantratitaN.. 2015. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand. Int. J. Antimicrob. Agents, 45:557–559.
16.
DanceD.A., DavongV., SoengS., PhetsouvanhR., NewtonP.N, and TurnerP.. 2014. Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei. Int. J. Antimicrob. Agents, 44:368–369.
17.
DuttaS., HaqS., HasanM.R, and HaqJ.A.. 2017. Antimicrobial susceptibility pattern of clinical isolates of Burkholderia pseudomallei in Bangladesh. BMC Res. Notes, 10:299.
18.
RaoC., HuZ., ChenJ., TangM., ChenH., LuX., CaoL., DengL., MaoX., and LiQ.. 2019. Molecular epidemiology and antibiotic resistance of Burkholderia pseudomallei. isolates from Hainan, China: a STROBE compliant observational study. Medicine (Baltimore) 98:e1, 4461.
19.
KoshyM., JagannatiM., RalphR., VictorP., DavidT., SathyendraS., VeeraraghavanB., and VargheseG.M.. 2019. Clinical manifestations, antimicrobial drug susceptibility patterns, and outcomes in melioidosis cases, India. Emerg. Infect. Dis. 25:316–320.
20.
NhungP.H., VanV.H, AnhN.Q, and PhuongD.M.. 2019. Antimicrobial susceptibility of Burkholderia pseudomallei isolates in the Northern Vietnam. J. Glob. Antimicrob. Resist. 18:34–36.
21.
CLSI. 2018. Methods for Dilution Antimicrobial Susceptibility Tests for Bateria That Grow Aerobically, 11th ed. CLSI Standard M07. Clinical and Laboratory Standards Institute, Wayne, PA.
22.
ChirakulS., SomprasongN., NorrisM.H, WuthiekanunV., ChantratitaN., TuanyokA., and SchweizerH.P.. 2019. Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification. Int. J. Antimicrob. Agents, 53:582–588.
23.
RhodesK.A., and SchweizerH.P.. 2016. Antibiotic resistance in Burkholderia species. Drug Resist. Updat. 28:82–90.
24.
VibergL.T., SarovichD.S, KiddT.J, GeakeJ.B, BellS.C, CurrieB.J, and PriceE.P.. 2017. Within-host evolution of Burkholderia pseudomallei during chronic infection of seven Australasian cystic fibrosis patients. mBio, 8:e00356-17.
25.
SarovichD.S., WebbJ.R, PitmanM.C, VibergL.T, MayoM., BairdR.W, RobsonJ.M, CurrieB.J, and PriceE.P.. 2018. Raising the stakes: loss of efflux pump regulation decreases meropenem susceptibility in Burkholderia pseudomallei. Clin. Infect. Dis. 67:243–250.
26.
PriceE.P., VibergL.T, KiddT.J, BellS.C, CurrieB.J, and SarovichD.S. 2018. Transcriptomic analysis of longitudinal Burkholderia pseudomallei. infecting the cystic fibrosis lung. Microb. Genom. 4: e00, 0194.
27.
DanceD.A., WuthiekanunV., ChaowagulW., and WhiteN.J.. 1989. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24:295–309.
28.
BugryshevaJ.V., SueD., GeeJ.E, ElrodM.G, HoffmasterA.R, RandallL.B, ChirakulS., TuanyokA., SchweizerH.P, and WeigelL.M.. 2017. Antibiotic resistance markers in Burkholderia pseudomallei strain Bp1651 identified by genome sequence analysis. Antimicrob. Agents Chemother. 61:e00010-17.
PodinY., SarovichD.S, PriceE.P, KaestliM., MayoM., HiiK., NgianH., WongS., WongI., WongJ., MohanA., OoiM., FamT., WongJ., TuanyokA., KeimP., GiffardP.M, and CurrieB.J.. 2014. Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. Antimicrob. Agents Chemother. 58:162–166.
31.
TribuddharatC., MooreR.A, BakerP., and WoodsD.E.. 2003. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47:2082–2087.
32.
SamI.C., SeeK.H, and PuthuchearyS.D.. 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol. 47:1556–1558.
33.
RhollD.A., Papp-WallaceK.M, TomarasA.P, VasilM.L, BonomoR.A, and SchweizerH.P.. 2011. Molecular investigations of PenA-mediated beta-lactam resistance in Burkholderia pseudomallei. Front. Microbiol. 2:139.
34.
ChirakulS., NorrisM.H, PagdepanichkitS., SomprasongN., RandallL.B, ShirleyJ.F, BorleeB.R, LomovskayaO., TuanyokA., and SchweizerH.P.. 2018. Transcriptional and post-transcriptional regulation of PenA beta-lactamase in acquired Burkholderia pseudomallei beta-lactam resistance. Sci. Rep. 8:10652.
35.
ChantratitaN., RhollD.A, SimB., WuthiekanunV., LimmathurotsakulD., AmornchaiP., ThanwisaiA., ChuaH.H, OoiW.F, HoldenM.T, DayN.P, TanP., SchweizerH.P, and PeacockS.J. 2011. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U.S.A. 108: 17165–1, 7170.
36.
PodneckyN.L., RhodesK.A, MimaT., DrewH.R, ChirakulS., WuthiekanunV., SchuppJ.M, SarovichD.S, CurrieB.J, KeimP., and SchweizerH.P.. 2017. Mechanisms of resistance to folate pathway inhibitors in Burkholderia pseudomallei: deviation from the Norm. mBio, 8:e01357-17.
37.
WebbJ.R., PriceE.P, CurrieB.J, and SarovichD.S.. 2017. Loss of methyltransferase function and increased efflux activity leads to doxycycline resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 61:e00268-17.
38.
MooreR.A., DeShazerD., ReckseidlerS., WeissmanA., and WoodsD.E.. 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43:465–470.
39.
TrunckL.A., PropstK.L, WuthiekanunV., TuanyokA., Beckstrom-SternbergS.M, Beckstrom-SternbergJ.S, PeacockS.J, KeimP., DowS.W, and SchweizerH.P.. 2009. Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl. Trop. Dis. 3:e519.
40.
RhodesK.A., SomprasongN., PodneckyN.L, MimaT., ChirakulS., and SchweizerH.P.. 2018. Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology, 164:1156–1167.
41.
MimaT., and SchweizerH.P.. 2010. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob. Agents Chemother. 54:3113–3120.
PriceE.P., SarovichD.S, MayoM., TuanyokA., DreesK.P, KaestliM., Beckstrom-SternbergS.M, Babic-SternbergJ.S, KiddT.J, BellS.C, KeimP., PearsonT., and CurrieB.J.. 2013. Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. mBio, 4:e00388-13.
45.
Department of HealthU.S and Services.Human. 2009. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 5th ed. U.S. Department of Health and Human Services, Washington, DC.
46.
CLSI. 2015. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, 3rd ed. CLSI Guideline M45. Clinical and Laboratory Standards Institute, Wayne, PA.
47.
LonswayD.R., ElrodM.G, KendrickN., TillerR., SullivanM.M, EdwardsJ.R, BlaneyD.D, and KarlssonM.. 2019. Correlation between Etest and reference broth microdilution for antimicrobial susceptibility testing of Burkholderia pseudomallei. Microb. Drug Resist. 26:311–318.
48.
CLSI. 2019. Performance Standards for Antimicrobial Susceptibility Testing, 29th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
49.
EUCAST. 2020. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 10.0. The European Committee on Antimicrobial Susceptibility Testing. Available at https://www.eucast.org/clinical_breakpoints
JohnsonS.L., Bishop-LillyK.A, LadnerJ.T, DaligaultH.E, DavenportK.W, JaissleJ., FreyK.G, KorolevaG.I, BruceD.C, CoyneS.R, BroomallS.M, LiP.E, TeshimaH., GibbonsH.S, PalaciosG.F, RosenzweigC.N, ReddenC.L, XuY., MinogueT.D, and ChainP.S.. 2015. Complete genome sequences for 59 burkholderia isolates, both pathogenic and near neighbor. Genome Announc. 3:e00159-15.
52.
MichelP.A., LascolsC., GeeJ.E, WeigelL.M, and SueD.. 2017. Rapid filter-based detection and culture of Burkholderia pseudomallei from small volumes of urine. J. Clin. Microbiol. 55:2698–2707.
53.
McLaughlinH.P., CherneyB., HakovirtaJ.R, PriestleyR.A, ConleyA., CarterA., HodgeD., PillaiS.P, WeigelL.M, KershG.J, and SueD.. 2017. Phylogenetic inference of Coxiella burnetii by 16S rRNA gene sequencing. PLoS One, 12:e0189910.
54.
AmblerR.P., CoulsonA.F, FrereJ.M, GhuysenJ.M, JorisB., ForsmanM., LevesqueR.C, TirabyG., and WaleyS.G.. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276,(Pt 1)::269–270.
55.
PodneckyN.L., RhodesK.A, and SchweizerH.P.. 2015. Efflux pump-mediated drug resistance in Burkholderia. Front. Microbiol. 6:305.
56.
KaratunaO., DanceD.A.B, MatuschekE., AhmanJ., TurnerP., HopkinsJ., AmornchaiP., WuthiekanunV., CusackT.P, BairdR., HennessyJ., NortonR., ArmstrongM., ZangeS., ZoellerL., WahabT., JacobD., GrunowR., and KahlmeterG.. 2020. Burkholderia pseudomalleimulti-centre study to establish EUCAST MIC and zone diameter distributions and epidemiological cut-off values. Clin. Microbiol. Infect. [Epub ahead of print]; DOI: 10.1016/j.cmi.2020.07.001.
57.
LipsitzR., GargesS., AurigemmaR., BaccamP., BlaneyD.D, ChengA.C, CurrieB.J, DanceD., GeeJ.E, LarsenJ., LimmathurotsakulD., MorrowM.G, NortonR., O'MaraE., PeacockS.J, PesikN., RogersL.P, SchweizerH.P, SteinmetzI., TanG., TanP., WiersingaW.J, WuthiekanunV., and SmithT.L.. 2012. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei, Infection, 2010. Emerg. Infect. Dis. 18:e2.
58.
DallasS.D., McGeeL., LimbagoB., PatelJ.B, McElmeelM.L, FulcherL.C, LonswayD.R, and JorgensenJ.H.. 2013. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J. Clin. Microbiol. 51:1798–1802.
59.
MaalandM.G., PapichM.G, TurnidgeJ., and GuardabassiL.. 2013. Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. J. Clin. Microbiol. 51:3547–3554.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
